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Background: Statins are the standard of care for subjects with or at high
risk of cardiovascular disease. However, cardiovascular risk among subjects
on lipid-lowering drugs remains high and has been called residual risk. In a
representative sample of the French population, we explored the long-term
impact on mortality of high triglycerides (TG) and low HDL-cholesterol
(HDL-C).
Methods: A sample of men and women, aged 35-64 years, was randomly
selected in 1995-1997. People were extensively described as regard to their
cardiovascular risk factors, lifestyle habits and use of drug treatments. A
fasting blood sample was drawn for plasma lipids and glucose measurement.
Risk of total mortality was assessed by univariate and multivariate Cox pro-
portional hazard models.
Results: The median follow-up of the 3446 subjects was 15.8 years [mean
15.2 years, standard deviation: 2.5]. We registered 348 deaths. Unadjusted
hazard ratio for total mortality was 2.09 (1.49-2.93, p<0.001) for TG >200mg/dL
vs TG ≤200mg/dL and was 1.44 (1.02-2.03, p<0.04) for HDL-C <40mg/dL in
men or <50 mg/dL in women vs HDL-C ≥40 mg/dL in men or ≥50 mg/dL in
women. Because of an interaction between TG and HDL-C on long-term mor-
tality, a stratified analysis was performed. After adjustment for age, sex, region,
smoking, treated hypertension, treated diabetes and lipid-lowering drugs, multi-
variate hazard ratio was 1.50 (1.05-2.13, p<0.03) for TG >200 mg/dL and HDL-
C ≥40/50 mg/dL, 1.25 (0.77-2.03, NS) for TG >200 mg/dL and HDL-C <40/50
mg/dL, 1.25 (0.88-1.77, NS) for TG ≤200 mg/dL and HDL-C <40/50 mg/dL, in
comparison with TG ≤200 mg/dL and HDL-C ≥40/50 mg/dL.
Conclusions: Hypertriglyceridemia was an important marker of cardio-
vascular risk in this general population. Residual risk on lipid-lowering drugs
might be related to achieved LDL-cholesterol but might also be linked to
uncontrolled and mildly elevated triglycerides.
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Purpose: Left ventricular hypertrophy (LVH) detected on a resting ECG,
and abnormal urinary albumin/creatinine ratio (uACR), are known to be cor-
related and both predictive of cardiovascular events in type 2 diabetes mellitus
patients (T2D). Our study aimed to assess their respective prognostic values
in a cohort of T2D.
Methods: A total of 1410 T2D (43% women, mean age 65±11 years) were
followed for a median period of 59 months, with a primary composite end-
point of: cardiovascular death, myocardial infarction or stroke. ECG-LVH was
defined by one of the following indexes: Sokolow voltage >35 mV or Gübner
voltage >25 mV or Cornell product >2440 mV.ms; uACR was considered as
abnormal if >2.5 mg.mmol-1 in men or >3.5 mg.mmol-1 in women.
Results: The ECG-LVH prevalence was 16%, higher in women (19%)
than in men (14%). (P=0.005). Determinants of LVH were female gender,
age, diabetes duration, and renal dysfunction. Median [IQR] uACR was 3.03
[12.83] mg/mmol, higher in subjects with LVH (7.32 [43.02]) than in subjects
without (2.66 [10.37]) (P<0.0001). Regarding the composite end-point, LVH
(adj HR=1.89; P<0.0001) and abnormal uACR (HR =1.65; P=0.001) were
strong, and independent in predictors for the primary endpoint after adjust-
ment for age, history of coronary heart disease or peripheral artery disease and
eGFR, respectively) (Table 1).
Conclusion: ECG-derived LVH and uACR are both independent and
complementary predictors for cardiovascular outcomes in T2D patients.
Table 1- Clinical and biological covariates of primary outcome. Cox multiva-
riate analysis
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Purpose: We aimed at describing the achievement of targets for controlling
cardiovascular risk factors among diabetic subjects from a population-based
sample, using the recent updated European Society of Cardiology guidelines
for cardiovascular prevention, as reference. 
Methods: A sample of 4769 men and women, aged 35-74 years, was ran-
domly selected in 2005-2007 by drawing on polling lists. People were exten-
sively described as regard to their cardiovascular risk factors, lifestyle habits
and use of drug treatments. A fasting blood sample was drawn for plasma
lipid, haemoglobin A1c and glucose measurement. 
Results: The prevalence of diabetes (defined as the use of hypoglycaemic
drugs or fasting glycaemia ≥7 mmol/l) was 5.9% in this middle-age sample
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Parameters Coefficient P-value Adj HR 95% CI
Age > 65 years 0.674 <0.0001 1.962 1.485-2.593
Diabetic retinopathy 0.447 0.003 1.564 1.164-2.101
History of coronary heart 
disease
0.557 0.0002 1.745 1.297-2.349
History of peripheral artery 
disease
0.705 <0.0001 2.024 1.425-2.874
eGFR MDRD < 60 mL.min-
1
.1.73m-²
0.522 0.0002 1.686 1.283-2.215
Abnormal uACR 0.580 <0.0001 1.786 1.334-2.390
ECG-LVH (combined 3 criteria) 0.488 0.001 1.628 1.207-2.198
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[95% confidence interval: 5.3%-6.6%], with 95% of diabetics considered as
being at very high risk (combining diabetes plus documented cardiovascular
disease, or one or more associated cardiovascular risk factor(s), or chronic
kidney disease). The percentage of diabetics achieving the target for haemo-
globin A1c (<7%) was 64.5%, varying according to the level of risk (87%
among high risk and 63% among very high risk diabetics, p=0.065), and
according to drug treatment (83% among untreated diabetics, 75% among
those treated with one oral hypoglycaemic agent, 49% for a combination of
two oral agents, 19% for a combination of three, and 37% among people
under insulin-based hypoglycaemic treatment, p<0.0001). Control of associ-
ated risk factors was poor: only 19% of diabetics reached the target for blood
pressure (<140/80 mmHg), 27% had LDL-cholesterol <2.5 mmol/l and 4%
had LDL-cholesterol <1.8 mmol/l. 
Conclusions: In this sample, control of cardiovascular risk factors is wor-
rying among diabetic patients, with about two thirds only achieving haemo-
globin A1c target, one fifth presenting with controlled blood pressure and a
quarter achieving LDL-cholesterol below 2.5 mmol/l. 
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Systematic cardiologic evaluation in HIV-infected patients in primary
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Background: Human Immunodeficiency Virus (HIV) Infection became a
chronic disease. Cardiovascular diseases became a frequent complication. The
purpose of this study is to estimate the utility of systematic screening for isch-
emic heart disease and cardiovascular events .
Methods: We proposed a consultation in cardiology to HIV-infected
patients with measurement of ankle brachial index, an electrocardiogram, an
echography and a stress test coupled with a myocardial scintigraphy.
Results: We recorded 147 HIV-infected patients. Cardiovascular risk fac-
tors are essentially marked by important smoking (51%), hypercholesterol-
emia (28%) and hypertension (33%). We noted 5 cardiovascular events.
41 patients (28%) have clinical or sub clinical disease including left ventri-
cular hypertrophy, diastolic dysfunction, atrial fibrillation and vascular
peripheric disease. Predictive factors of cardiovascular events are age, high
blood pressure, treatment by aspirin, clopidogrel ACE-inhibitors/angiotensin
II, creatinine rate, longer of seropsitivity, negatives T waves, Q waves, time
of deceleration of E wave and high risk cardiovascular score. Multivariate
analyse found as independent predictive factors of subclinical or clinical car-
diovascular disease: time of deceleration E wave, blood systolic and diastolic
pressure, negatives T waves, ACE-inhibitors/angiotensin II. DAD score and
SCORE are not useful because only 9 patients are considered as high or very
high cardiovascular risk.
Conclusion: Cardiologic evaluation in HIV-infected patients can detect
cardiovascular risk factors and 28% of clinical or subclinical cardiovascular
disease. 
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Objective: To evaluate the quality of vitamin K antagonists (VKA) control
in very elderly patients in geriatrics setting and to assess the characteristics
associated with VKA control.
Design: National cross-sectional survey.
Settings: Patients aged 80 years or more, hospitalized or institutionalized
in rehabilitation care or long-term settings and who were treated by VKA. 
Participants: 2633 patients were included. Clinical and biological infor-
mation was collected through a standardized questionnaire. 
Measurements: Time in therapeutic range (TTR) was computed according
to the Rosendall's method.
Results: The mean (SD) age was 87.2 (4.4) years and 72.9% of the patients
were women. Atrial fibrillation represented 71.4% of the indications for VKA
therapy. The most prescribed VKA was Fluindione (64.9%). The mean (SD)
TTR was 57.9 (40.4)%. After backward logistic regression (TTR < 50% vs.
≥50%), poorer VKA control was associated with the indication for VKA treat-
ment (prosthetic heart valve vs. AF; OR=4.86 ; 95% CI=2.87-8.24), the type
of VKA used (Fluindione vs. Warfarin; OR=1.26; 95% CI=1.03-1.54, and
Acenocoumarol vs. Warfarin; OR=1.68; 95% CI=1.01-2.79), a history of INR
> 4.5 (yes vs. no; OR=1.37; 95%CI=1.11-1.69), antibiotics use (yes vs. no;
OR=1.63; 95% CI=1.10-2.41) and falls (≥2 falls during the past year vs. < 2;
OR=1.26; 95% CI=1.01-1.56). Conversely, a longer test interval was associ-
ated with better VKA control (≥9 vs. < 9 days; OR=0.41; 95%CI =0.34-0.49).
Conclusion: Overall VKA control remains insufficient in very old patients.
Poorer VKA control was associated with taking VKA for a prosthetic heart
valve, the use of other VKAs than warfarin, a shorter interval between INR
tests, and a history of overcoagulation, antibiotics use and falls.
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Background: A shorter time delay between onset of symptoms and first
call to medical attention would be expected in patients with a history of
ischemic heart disease (IHD), compared with patients not known to have IHD,
either because they have already experienced an AMI or because their GPs/
cardiologists would have educated them to recognize symptoms of AMI. The
aim of this study was to determine whether time to first call for a STEMI dif-
fered between patients with or without history of coronary artery disease.
Methods and Results: FAST-MI 2010 is a nationwide French registry that
included 4169 patients with AMI at the end of 2010 in 213 centres. These com-
prised 2364 STEMI patients. Factors correlated with time to first call were
assessed, with a specific emphasis on previous history of IHD (IHD + n=382),
compared with patients without history of IHD (IHD– n=1982). Time from
onset to first call (TOFC) was 245±453 min (median 75 min) in IHD+ patients
vs 246±431 min (median 75 min) in IHD– patients (P=0.95). TOFC was
≤60 minutes in 48% of IHD+ patients and in 47% of IHD– patients (P=0.77);
TOFC was ≤ 120 minutes in 66% and 63%, respectively (P=0.33). Only few
factors were significantly related to a shorter TOFC: greater chest pain intensity
(P<0.001), diurnal onset of symptoms from 7:00 am to 11:00 pm (P<0.001),
syncope/cardiac arrest as initial symptom (P<0.001), anterior location of MI
(P=0.004), higher Killip class on admission (P=0.02), and not living alone
(P=0.03). With the only exception of chronic treatment with aspirin (P=0.03),
none of the medications used before onset of AMI was associated with a shorter
TOFC. Similar results were found when time to first call was compared in
patients with (n=517) or without any cardiovascular history (IHD or peripheral
artery disease or cerebrovascular disease): median time 75 min in each group.
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Conclusions: Patients with a history of IHD do not call earlier than IHD-
naïve patients when they are confronted with symptoms of AMI. Cardiologists
should spend more time to educate their coronary patients to recognize symp-
toms of AMI.
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Purpose: Conduit vessel non-compliance and endothelial dysfunction may
be manifestations of a similar process which lead to atherosclerosis. Statin
therapy may have beneficial effects on these parameters, despite adverse effects
on muscle function. We sought to study the effect of statin therapy on endothe-
lial function, aortic stiffness, and their potential impact on exercise tolerance.
Methods: In this double-blind, placebo-controlled trial, 22 patients with
primary untreated hypercholesterolemia and free of other risk factors or car-
diovascular disease (56±9 years, 12 men, BMI: 27±4 kg.m-2, blood pressure:
127/79±12/5 mmHg) were randomized 1:1 to placebo or pravastatin 40 mg
daily for 12 weeks. Endothelial function (ultrasound-guided brachial artery
flow mediated dilatation (FMD)), aortic stiffness (tonometry-derived carotid-
femoral pulse wave velocity (cfPWV)), and submaximal and maximal exer-
cise tolerance were measured.
Results: Despite a significant reduction in total and LDL-cholesterol in the
treatment group (total-cholesterol: 6.18±0.94 vs. 5.23±0.79 mmol.L-1, P=0.03;
LDL: 4.15±0.72 vs. 3.03±0.73 mmol.L-1, P=0.005 in placebo and treatment
groups respectively), no between-group differences were observed for
endothelial function (FMD: 10.05±4.73 vs. 9.23±2.90%, P=0.8), vascular
compliance (cfPWV: 8.50±2.07 vs. 8.65±2.12 m.s-1, P=0.9), submaximal (sub-
maximal exercise time: 1229±862 vs. 1561±948 sec, P=0.5), or maximal exer-
cise tolerance (VO2 peak: 25.59±4.60 vs. 28.93±9.62 mL.min-1.kg-1, P=0.7).
However, we observed in pre/post comparisons, a significant decrease in VO2
peak in the statin group (29.07±6.20 vs. 25.59±4.60 mL.min-1.kg-1, P=0.008)
and an improvement in VO2 peak in the placebo group (26.86±9.00 vs.
28.93±9.62 mL.min-1.kg-1, P=0.005).
Conclusion: In patients with previously untreated hypercholesterolemia,
12-weeks of statin therapy had no effect on endothelial function or arterial
stiffness, but had deleterious effects on maximal exercise tolerance.
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service based on an interoperability platform
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The need for exchanging medical information becomes – for health care
coordination as well as for pooling research protocols – a growing need in
patients with serious cardiologic diseases requiring European mobility. This
need is facing difficulty to combine in Europe on a single medium documents
and dynamic images from hospital health systems, due to the lack of a single
European health identifier and to delays in setting up an effective standardiza-
tion of exchanges in most of the European facilities and health institutions.
The technologies used in this project are based on a server (“Access Box”)
set up in any European Partner Hospital (EPH), allowing for any patient
requiring access to this service, and volunteer: 
1/ to initiate the process inside the EPH from a smartphone or a tablet
assigned to the patient. The device is identified through a SDI (Single Device
Identifier), and the patient through a biometric (facial or fingerprint) recogni-
tion algorithm and a password; 
2/ to collect from the Access Box documents, structured information and
images (static and dynamic)  included in the EPH information system and
DICOM servers; 
3/ to convert them into a transport (IHE – XDS) and exchange (CDA – R2)
format, conforming to international medical interoperability standards; 
4/ to transfer, on the basis of a reconciliation between the SDI table and the
local patient health identifier of each EPH:
– documents to a “Document Repository” and images to a “DICOM Image
Repository” hosted by an accredited heath data webhost
– structured metadata to a pointers server integrating a relational database.
The expected impact is to provide a compatible iOS/Android/W8 applica-
tion, to allow patients with serious cardiologic diseases and in situation of
mobility through Europe to be identified by their own smartphone/tablet and
to access securely and share medical information and images through a user-
friendly interface
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Impact of the recent controversy over statins in France
Anis Saib, Laurent Sabbah, Ludivine Perdrix, Didier Blanchard, Nicolas
Danchin, Etienne Puymirat
Hôpital Européen Georges Pompidou (HEGP), Cardiologie, Paris, 
Background: The effect of statins on the prevention of cardiovascular
events is well demonstrated. However, a recent controversy in France ques-
tioned the interest of statins especially in primary prevention.
Aims: To evaluate the impact of this controversy on patient adherence to
statin therapy and the potential clinical impact.
Methods: All patients on statins were recruited consecutively from consul-
tations over a period of one month (from March 2013) by 5 physicians in
3 centers. Patient demographics and co-morbidities were collected and the
adherence to statin therapy was evaluated with a questionnaire. We estimated
the number of death and major cardiovascular disease (CVD) that could be
induced per year by this controversy from current data.
Results: A total of 142 patients were included: 37 in primary prevention
(mean age 68.0±13.1, 41% women); 105, in secondary prevention (mean age
67.6±12.1, 20% women). In primary prevention, 24.3% of patients intended to
stop statins versus 8.6% in secondary prevention (p<0.001). En France, this
controversy could induce 4992 major CVD, including 1159 additional deaths
in one year whether patients stop really their statins.
Conclusion: Recent controversy over statins could induce a large proportion
of patients to stop their medication and generate a large number of major CVD.
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Coronary artery disease (CAD) risk increases with the elevation of Low-
lipoprotein cholesterol (LDL-c), triglyceride (TG) and low level High-density
lipoprotein cholesterol (HDL-c) levels. A new index called chol-index, in
order to evaluate CAD risk, and investigated its reliability. The aim of this
study was to determine the index and its association with to the risk of devel-
oping CHD in our population.
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